1. Gurjar, Rohan, Dickinson, Laura, Carr, Daniel, Raffi, François, Boffito, Marta. 2022. Influence of UGT1A1 and SLC22A6 polymorphisms on the population pharmacokinetics and pharmacodynamics of raltegravir in HIV-infected adults: a NEAT001/ANRS143 sub-study. In The pharmacogenomics journal, 23, 14-20. doi:10.1038/s41397-022-00293-5. https://pubmed.ncbi.nlm.nih.gov/36266537/
2. Moss, Darren M, Kwan, Wai San, Liptrott, Neill J, Back, David J, Owen, Andrew. 2010. Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir. In Antimicrobial agents and chemotherapy, 55, 879-87. doi:10.1128/AAC.00623-10. https://pubmed.ncbi.nlm.nih.gov/21078936/
3. Vávra, Jiří, Mančíková, Andrea, Pavelcová, Kateřina, Bohatá, Jana, Stibůrková, Blanka. 2022. Functional Characterization of Rare Variants in OAT1/SLC22A6 and OAT3/SLC22A8 Urate Transporters Identified in a Gout and Hyperuricemia Cohort. In Cells, 11, . doi:10.3390/cells11071063. https://pubmed.ncbi.nlm.nih.gov/35406626/
4. Bhatnagar, Vibha, Xu, Gang, Hamilton, Bruce A, Wu, Wei, Nigam, Sanjay K. 2006. Analyses of 5' regulatory region polymorphisms in human SLC22A6 (OAT1) and SLC22A8 (OAT3). In Journal of human genetics, 51, 575-580. doi:10.1007/s10038-006-0398-1. https://pubmed.ncbi.nlm.nih.gov/16648942/
5. Torres, Adriana M, Dnyanmote, Ankur V, Bush, Kevin T, Wu, Wei, Nigam, Sanjay K. 2011. Deletion of multispecific organic anion transporter Oat1/Slc22a6 protects against mercury-induced kidney injury. In The Journal of biological chemistry, 286, 26391-5. doi:10.1074/jbc.M111.249292. https://pubmed.ncbi.nlm.nih.gov/21652719/
智鼠故事 
